Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

CALD1/IGF2BP1 complex mediates cisplatin resistance in bladder cancer via enhancing RFC4 mRNA stability in an m⁶A-dependent manner.

ABSTRACT: Cisplatin-based chemotherapy is the first-line treatment for muscle-invasive and metastatic bladder cancer, but most patients develop drug resistance within a short period. M⁶A modification (N⁶-methyladenosine) has been extensively validated as a key hallmark of multiple cancers, and its dysregulation may contribute to cisplatin resistance.

ORGANISM(S): Homo sapiens

PROVIDER: GSE313336 | GEO | 2025/12/16

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Characterization of the difference of mRNA and lncRNA profiling between cisplatin-resistance and regular T24 bladder cancer cells

Project description:To investigate the difference of mRNA and lncRNA profiling between cisplatin-resistance and regular T24 bladder cancer cells, T24 cells were treated with a gradual increment (4, 8, 16, 32, 64 ug/ml cisplatin) with a discontinuous period until cells recover. 10^6 cells T24R and T24 cells were harvested for RNA-seq.

2019-11-11 | E-MTAB-7437 | biostudies-arrayexpress

Downregulation of CBX7 induced by EZH2 upregulates FGFR3 expression to reduce sensitivity to cisplatin in bladder cancer

Project description:Cisplatin-based cytotoxic chemotherapy is considered to be the first-line therapy for advanced bladder cancer (BC), but resistance to cisplatin limits its antitumor effect. Fibroblast growth factor receptor 3 (FGFR3) has been reported to contribute to the progression and cisplatin resistance of BC. Meanwhile, chromobox protein homolog 7 (CBX7) was reported to inhibit BC progression. And our previous RNA-seq data on CBX7 (GSE185630) suggested that CBX7 might repress FGFR3，but the underlying mechanism and other cancer-related functions of CBX7 are still unknown.

2025-10-05 | GSE214886 | GEO

N6-methyladenosine RNA modification drives a rapid shift to cisplatin resistance in bladder cancer by regulating SLC7A11 expression via YTHDF3 [RNA-seq]

Project description:Our study examines the role of m6A RNA modification in regulating gene expression of transcripts promoting cisplatin resistance in bladder cancer.

2023-11-08 | GSE231835 | GEO

N6-methyladenosine RNA modification drives a rapid shift to cisplatin resistance in bladder cancer by regulating SLC7A11 expression via YTHDF3 [RIP-seq]

Project description:Our study examines the role of m6A RNA modification in regulating gene expression of transcripts promoting cisplatin resistance in bladder cancer.

2023-11-08 | GSE231834 | GEO

ITGB4 up-regulated by STAT3 reduces the sensitivity of bladder cancer to cisplatin by suppressing p53

Project description:Background: Cisplatin-based chemotherapy is the first-line treatment for patients with advanced bladder cancer (BC). However, the development of cisplatin resistance limits its antitumor effects. While, the mechanism of cisplatin resistance remains unclear. Methods: Bioinformatics techniques were used to analyze genes and pathways associated with cisplatin therapy resistance. A variety of biological techniques were used to identify the role of ITGB4 in cisplatin sensitivity in BC and its potential molecular mechanism. Results: In this study, we demonstrated that ITGB4 plays a key role in regulating the sensitivity of p53 wild-type (WT) BC to cisplatin therapy. Our findings revealed that ITGB4 reduces the sensitivity of BC to cisplatin by inhibiting phosphorylation of the p53-S15 site and promoting MDM2 binding to p53, thereby reducing p53 expression. Additionally, we showed that ITGB4 influences the antitumor effects of MDM2 inhibitors when they are combined with cisplatin therapy. Furthermore, we found that ITGB4 levels were elevated in cisplatin-resistant BC cells, a process mediated by STAT3 activation. The combination of STAT3 inhibitors can enhance the antitumor effect of cisplatin in BC. Conclusions: ITGB4 is a key molecule influencing cisplatin sensitivity in p53 WT BC, and the combination of STAT3 inhibitors can enhance the antitumor effect of cisplatin.

2024-06-07 | GSE268855 | GEO

Cisplatin resistance driver gene CLSPN product is a target for immunotherapy in urothelial carcinoma.

Project description:Bladder cancer is a major and mortal disease in urological area. Cisplatin is a key drug for bladder cancer especially for muscle invasive cases. In most cases of bladder cancer, cisplatin is effective; however, resistance to cisplatin is critical for patient’s prognosis. Thus, treatment strategy for cisplatin resistant bladder cancer is essential to improve current prognosis. In this study, we established cisplatin resistant bladder cancer line (CR cells) using a urothelial carcinoma line UM-UC-3 cells. We screened potential targets for CR cells and found that claspin is overexpressed in CR cells. Claspin mRNA knockdown revealed that claspin has a role in cisplatin resistance in CR cells. In our previous study, we found HLA-A*02:01-restricted CLSPN peptide by an HLA ligandome analysis. We thus generated CLSPN peptide specific CTL clone and found that CLSPN peptide-specific CTL clone recognized CR cells at higher levels compared with that of UM-UC-3 wild type cells. These findings indicate that claspin is a driver for cisplatin resistance and claspin peptide-specific immunotherapy is effective for cisplatin resistant cases.

2024-04-10 | GSE217413 | GEO

Integrated Analysis of Global Proteome and Phosphoproteome in Cisplatin Resistant Bladder Cancer Cell Revealed the Molecular Signature Predictive to Patient Survival

Project description:Cisplatin-based chemotherapy is the standard care regimen in bladder cancer (BC). However, resistance to the therapy whose molecular mechanisms of the resistance are not fully elucidated rapidly develops in BC patients. Here we introduced multidimensional proteomic analysis providing different levels of protein information, which included global proteome and phosphorpoteome perturbed by EGF using the cisplatin resistant BC model. Integrated analysis of protein expression and phosphorylation provided comprehensive profiles of altered proteins in cisplatin resistant cells that are dependent and independent on EGF, as well as suggesting significance of protein phosphorylation in resistance mechanisms in BC. From the reconstruction of cisplatin resistance associated network model and subsequent kinase enrichment analysis, we have identified three key kinases, CDK2, CHEK1, and ERBB2 as central regulators mediating cisplatin resistance. Experimental validation showed phosphorylation events in these central kinases and their putative substrates, suggesting evidence that activation of three kinases are important to acquired resistance to cisplatin in BC. Expanded analysis with this proteomic discovery to transcriptome profiles from BC cohorts nominated the 7 gene panel associated with poor survival after cisplatin-based chemotherapy. These findings provide insightful strategies to classify high-risk BC patients upon current chemotherapies and to identify therapeutic targets for recurrence disease.

2020-05-26 | PXD005308 | Pride

The M1 aminopeptidase NPEPPS is a novel regulator of cisplatin sensitivity

Project description:Platinum-based chemotherapeutics are used in many combination regimens in cancer. Despite extensive use across diverse cancer types, there is room for improved efficacy and patient selection for treatment. Here, we use bladder cancer to address both issues. A multi-omic assessment of five human bladder cancer cell lines and their chemotherapy resistant derivatives, coupled with in vitro whole-genome CRISPR screens were used to define functional drivers of treatment resistance. We identified 46 genes that sensitized the resistant cell lines to cisplatin plus gemcitabine (GemCis), a standard combination therapy in bladder cancer. Most genes were involved with DNA damage and repair pathways, which have previously been associated with enhanced sensitivity to cisplatin. Evaluating expression of the 46 genes in the whole transcriptome and proteome data in parental and resistant lines identified the puromycin sensitive aminopeptidase, NPEPPS, as a novel hit. Depletion of NPEPPS resulted in sensitizing resistant bladder cancer cells to cisplatin in vitro and in xenograft experiments. Pharmacologic inhibition of NPEPPS with tosedostat in cells and in chemoresistant, bladder cancer patient-derived tumoroids improved response to cisplatin. Prior work found NPEPPS in a protein complex with volume regulated anion channels (VRACs) in several cell line models. Interestingly, depletion of two VRAC subunits, LRRC8A and LRRC8D, known importers of intracellular cisplatin, enhanced resistance to cisplatin. Our findings support NPEPPS as a novel and druggable driver of cisplatin resistance with the potential for rapid translation to clinical investigation.

2024-02-20 | PXD024742 | Pride

N-acetyltransferase 10 drives cisplatin chemoresistance by enhancing ac4C-associated DNA repair in bladder cancer

Project description:To explore the molecular mechanism underlying NAT10-mediated cisplatin resistance in bladdder cancer, a genome-wide RNA-sequencing was conducted to compare gene expression profiles of T24 and UM-UC-3 cells with NAT10 knockdown and control. And acRIP-seq was performed to identified the downstream targets of NAT10.

2022-04-07 | GSE200285 | GEO

The M1 aminopeptidase NPEPPS is a novel regulator of cisplatin sensitivity

2023-12-31 | GSE171537 | GEO